Archive for ‘Oncology’

Page 1 of 3123

New Fluorescent Skin Dye to Replace Permanent Tattoos for Skin Cancer Treatment

New Fluorescent Skin Dye to Replace Permanent Tattoos for Skin Cancer Treatment

cancer-tattoo

 

Skin cancers, excluding melanoma, are often tracked by placing small tattoos near lesions that have been selected for further treatment. While they do their job as intended, the tattoos remain on the skin long after they’re needed and sometimes the inks can cause inflammation. Moreover, these tattoos can be confused as being lesions themselves at a later time.

A team headed by researchers at University of California, Los Angeles has come up with a new ink that can be used to temporarily mark the spot, and that is only visible when a light of specific wavelength (465 nanometers) is shined over it. Additionally, the ink is eventually washed away by the body so that it doesn’t create confusion in the future.

The new dye consists of cross-linked fluorescent supramolecular nanoparticles with a fluorescent conjugated polymer center. They have been shown to have a retention time by the body of around three months, a period similar to the time it takes in some places to go from a biopsy to treatment.

So far the researchers tested the new dye in laboratory mice, demonstrating that it works for three months and disappears thereafter, while not causing any nearby inflammation.

Study in ACS Nano: Cross-Linked Fluorescent Supramolecular Nanoparticles as Finite Tattoo Pigments with Controllable Intradermal Retention Times…

Via: American Chemical Society…

Full story

Teva to Distribute Pharmaceutical Grade Marijuana Dispenser

Teva to Distribute Pharmaceutical Grade Marijuana Dispenser

syqe-inhaler

 

Teva Pharmaceutical Industries, a famous Israeli pharma, is entering the medical marijuana industry by partnering with Syqe Medical, a company based in Tel Aviv, to distribute the Syqe inhaler. The Syqe inhaler is marketed as being the “world’s first selective-dose pharmaceutical grade medicinal plants inhaler,” capable of delivering marijuana to within 100 micrograms. There are two versions of the inhaler, including one for in-hospital use and one for patients to use at home.

The idea of a selective-dose inhaler is that it can be adjusted to deliver a nearly identical dose at every use. This is important since marijuana has psychoactive effects. The device allows to achieve the desired relief of whatever symptoms, such as nausea, that the marijuana is prescribed for, without producing excessive psychoactive effects for the patient.

Syqe will be producing the preloaded cartridges with pharmaceutical grade marijuana packed inside. The cartridges are childproof and only work inside the Syqe inhaler.

Full story

Diagnostic Imaging Device Market on Track to US$ 35,793.4 Million by 2020

Diagnostic Imaging Device Market on Track to US$ 35,793.4 Million by 2020

Infusion-pumps

 

The global diagnostic imaging devices market is growing at a moderate rate owing to increasing prevalence of chronic diseases and injuries, and growing aging population. Moreover, factors such as rising initiatives undertaken by government associations to boost awareness of the effects and complications of tuberculosis, cardiovascular diseases, and cancer, and technological advancement and widening application of diagnostic imaging devices are driving the global diagnostic imaging devices market. In addition, increasing funding from government bodies is also promoting the use of diagnostic imaging devices in the regions. However, factors such as strict regulatory requirements and heightened risk of cancer owing to exposure to radiation are inhibiting the market growth.

The global diagnostic imaging devices market was valued at USD 26,477.1 million in 2014 and is expected to grow at a CAGR of 5.2% from 2014 to 2020, to reach an estimated value of USD 35,793.4 million in 2020.

In Europe, the diagnostic imaging devices market is driven by rising diagnostic requirements due to increasing prevalence of chronic diseases and injuries, and aging population. For instance, according to a paper published on Cancer Incidence and Mortality Pattern in Europe, by International Agency for Research on Cancer in France, approximately, 3.45 million new cases of cancer were diagnosed in Europe in 2012.

In North America, growing aging population, increasing health awareness, rising chronic diseases and injuries, large number of ongoing research activities and faster adoption of technologically advanced imaging systems are driving the use of diagnostic imaging devices in the market.

Request to view Table of Content @ http://www.persistencemarketresearch.com/market-research/diagnostic-imaging-devices-market/toc

However, in Asia-Pacific the growth for diagnostic imaging devices is much higher than developed countries due to growing awareness about benefits of early diagnosis of disease among individuals, large population base, upgradation of health care systems and increasing prevalence of chronic diseases.

To Purchase Single User License @ http://www.persistencemarketresearch.com/checkout/2822

Siemens Healthcare, Hitachi, Ltd., Carestream, Health, Inc., Samsung Electronics Co., Ltd., Toshiba Corporation, Koninklijke Philips N.V., and General Electric Company are some of the major players in diagnostic imaging devices market.

About Us

Persistence Market Research (PMR) is a full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. PMR boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients’ business needs.

PMR stands committed to bringing more accuracy and speed to clients’ business decisions. From ready-to-purchase market research reports to customized research solutions, PMR’s engagement models are highly flexible without compromising on its deep-seated research values.

Contact

Persistence Market Research

305 Broadway

7th Floor, New York City,

NY 10007, United States

USA – Canada Toll Free: +1 800-961-0353

Email: sales@persistencemarketresearch.com

media@persistencemarketresearch.com

Web: http://www.persistencemarketresearch.com

Full story

ProNova SC360, a New Proton Therapy System Cleared in U.S.

ProNova SC360, a New Proton Therapy System Cleared in U.S.

sc360

 

ProNova Solutions, a division of Provision Healthcare based in Tennessee, won FDA clearance for its ProNova SC360 proton therapy system. It took the firm only four years to develop the system and get it cleared, but Tennessee is famous for its high energy physics expertise, going back to the Manhattan Project. The first SC360 installation already happened at the Provision CARES Proton Therapy Center in Knoxville, TN and the first patients are expected to be treated in the coming year.

The ProNova SC360 allows patients to be treated at any angle without having to move them, instead directing the beam to come from any direction chosen by the clinical team. This should allow for faster treatment times as patients don’t have to be repositioned to deliver energy from different angles.

It features pencil beam scanning and a built-in cone-beam CT for imaging the patients. Positron emission tomography (PET) capabilities are optionally available as well.

The system is designed to be able to power two treatment rooms at the same time, but single and three-room options can be made available as well.

Product page: ProNova SC360…

Via: Provision Healthcare…

Full story

DiCoMo’s Novel X-Ray Detector Technology to Allow for Low-Dose, High-Resolution Imaging and Diagnosis

DiCoMo’s Novel X-Ray Detector Technology to Allow for Low-Dose, High-Resolution Imaging and Diagnosis

image1

 

The DiCoMo (“Direct conversion hybrid-organic X-ray detectors on metal oxide backplane”) Project promises to remove the need for diagnosticians to reconcile the value of high-resolution scanning with the safety concerns associated with exposure to high doses of ionizing radiation through the development of a novel X-ray detector. Their flat panel digital X-ray detector technology draws upon advancements in photonics to improve the specificity and sensitivity of low-radiation scanning systems, thereby enabling low-cost, effective diagnosis and preventive care without endangering patients or radiology staff.

Essential radiographic imaging techniques such as X-ray and X-ray computed tomography (CT) scanning allow for visualization of internal structures by penetrating tissues with high-energy particles that produce harmful ionizing radiation. With traditional radiography systems, higher doses of radiation are required to image at high-resolution. However, additional radiation exposure creates extra risks of health consequences. As such, medical professionals are currently forced to mediate the risk and reward trade off on an application-specific basis, selecting a scanning configuration and detector type that is appropriate for visualizing a given structure or phenomenon.

Some common X-ray scanning techniques require high-resolution imaging to be of value, such as mammograms taken to evaluate or screen breast tissue for irregularities. This type of scan traditionally relies on detectors utilizing direct converters. Direct converters translate absorbed X-rays into electrical signals directly, requiring a heavy dose of X-rays and associated radiation in order to maximize spatial resolution. For other applications, especially those seeking to examine bones or other large structures through radiography or fluoroscopy, low-radiation, lower-resolution imaging is often suitable. Such scans employ detectors with indirect converters. In indirect conversion, scintillators produce light upon absorbing X-rays and the electrical signals are ultimately recorded by a photodetector. However, the scintillators create light in all directions upon X-ray irradiation, causing neighboring photodetector array pixels to register a signal, which, in aggregate, lowers the imaging resolution.

detector-dicomoThe DiCoMo Project, a consortium of European partner organizations and institutions coordinated in Germany by Siemens Healthineers, is working towards the development of an alternative, hybrid detector technology. Their detector is said to rely on “quasi-direct” conversion that allows for low-dose, high-resolution imaging. In the DiCoMo detector, the scintillator is embedded into the photodetector. This positioning limits light absorption and signal detection to the exact pixel that each X-ray photon irradiates. Additionally, active pixel sensors amplify the detected signals within each pixel via metal-oxide thin-film transistors, creating a stronger signal. Finally, a custom readout chip helps to more than double traditional detection frame rates, from approximately 60 frames per second (fps) to 130 fps. Taken together, the advanced detector technology thereby enables an unprecedented combination of high-resolution and low-radiation X-ray imaging, and is even capable of capturing fast-moving features.

In 2015, DiCoMo received significant research and innovation funding from the Photonics Public Private Partnership and the European Commission’s Horizon 2020 program. The consortium aims to leverage this funding and its existing progress to complete development of the new X-ray detectors within five years.

For additional Medgadget coverage of Photonics21 and Horizon 2020 projects, refer to this week’s story regarding how the COBIOPHAD device promises quicker, more efficient drug allergy diagnosis.

Press Release: High resolution detectors to create safer X-ray diagnosis…

More Information: DiCoMo…

Full story

Measuring Blood Flow from Conventional Color Doppler Ultrasound

Measuring Blood Flow from Conventional Color Doppler Ultrasound

blood-flow-from-ultrasound

 

Measuring intravascular blood flow is currently only possible with invasive methods. Swiss researchers from École polytechnique fédérale de Lausanne (EPFL) and Geneva University Hospital decided to see whether color Doppler ultrasound data holds enough information to derive the velocity of blood flowing through a vessel. They created a mathematical model of the vessels and blood within, and how ultrasound interacts with them. The results are pretty impressive, though not accurate enough for clinical use, and point to the possibility of one day getting accurate blood flow gauging from existing hardware.

Here’s a video of the software processing color Doppler data from a conventional clinical ultrasound transducer:

Link to study: A feasability study of color flow doppler vectorization for automated blood flow monitoring…

More info: Automated Blood Flow Monitoring from Color Flow Doppler Vectorization…

Full story

New Implantable Capsule for Killing Tumors, Managing Chronic Diseases

New Implantable Capsule for Killing Tumors, Managing Chronic Diseases

min-invasive-device

 

Researchers from University of Texas at San Antonio and Houston Methodist Research Institute have developed a new injectable drug delivery capsule that can administer medication locally for extended periods of time. The device, reported on in Journal of Biomedical Nanotechnology, has approximately 5,000 microscopic channels through which a drug is pumped and a special membrane that regulates how fast the medication is delivered.

The device can be made to deliver just about any drug at a pre-programmed rate. This can be particularly useful for attacking tumors due to the localized nature of the implanted capsule, but also for other conditions in which a constant, guaranteed regimen is critical to successful management of a disease. Additionally, imaging contrast agents can also be administered via the capsule.

The device is implanted using a common percutaneous trocar, so if and when it does reach the clinic it will be easy to introduce into practice. So far it’s been tested in vivo on laboratory animals, and the researchers are already working on a biodegradable version of the device that wouldn’t require explantation. Perhaps clinical in-human studies will come soon as well.

Study in Journal of Biomedical NanotechnologyNanochannel Implants for Minimally-Invasive Insertion and Intratumoral Delivery…

Via: University of Texas at San Antonio…

Image credit: Giacomo Bruno and Stefania Bruno

Full story

Angiogenesis Inhibitors and Stimulators Market Shows a Constant Growth with the Increasing Number of Cancer Cases

Angiogenesis Inhibitors and Stimulators Market Shows a Constant Growth with the Increasing Number of Cancer Cases

Non-Rhabdomyosarcoma

 

Angiogenesis is a physiological process that is associated withthe formation of new blood vessel from existing blood vessels. Angiogenesis process is commonly categorized into two types namely sprouting angiogenesis and intussusceptive angiogenesis. Sprouting angiogenesis is a fundamental mechanism of vessel growth in which formation of new blood vessel is regulated by sequential steps. Intussusceptive angiogenesis (also called as splitting angiogenesis) is referred where new blood vessel is created by internal division of an existing blood vessel.

Obtain the Forthcoming Market Projections for Angiogenesis Inhibitors and Stimulators at:http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1108

In contrast to sprouting angiogenesis, intussusceptive do not need local endothelial cell proliferation. Angiogenesis is mainly associated with the diverse set of conditions such as age related macular degradation, rheumatoid arthritis, cancer and psoriasis.The main focus of angiogenesis therapy is to shrink the existing tumor by aninhibitor or to meet the demand of under perfused region through generating new vessels by angiogenesis stimulator. Avastin (bevacizumab), Gleevec, Tarceva and Iressa are some of the largest selling angiogenesis inhibitor drugs worldwide.

Research and development activitiesfor the development of novel angiogenesis drugs for cancer treatment is the highest.Thus, increasing number of cancer cases will drive the growth of this market during the forecast period. According to World Health Organization, approximately 8.2 million deaths are reported in the year of 2012 due to cancer. Also it is predicted that, the annual cancer cases are expected rise from14 million to 22 million in next two decades. In addition, National Cancer Institute states that there are approximately 1,660,290 cases reported in the United States in 2013.Technological advancement will further boost the growth of angiogenesis inhibitor and stimulatorsmarket.For example, research in angiogenesis has enabled identification of several angiogenesis agonist and antagonist. However, high cost of these drugs will restrain the growth of this market.

Geographically, North America represents the largest market, followed by Europe for angiogenesis inhibitors and stimulatorsdue to large patient base and rise in treatment seeking population in these regions. The market of angiogenesis inhibitors and stimulators in Asia-Pacific countries such as India and China, South East Asian countries holds a strong growth as there is a rise in total number of newly diagnosed patient population of cancer in this region. According to World Health Organization, 60% of the world’s total annual cases of cancer occur in Africa, Asia and South America.

Some of the key players in the Angiogenesis Inhibitors and Stimulators market comprises Abbott Laboratories, Adnexus Therapeutics, Inc., F. Hoffman-La Roche, Ltd., Genentech, Inc., Amgen, Inc., AstraZeneca Plc., Novartis AG, Pfizer, Inc., Chugai Pharmaceutical Co., Ltd., EntreMed, Inc. and Eyetech, Inc.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Full story

Accuray’s New TomoTherapy H Series of Radiation Oncology Devices

Accuray’s New TomoTherapy H Series of Radiation Oncology Devices

Accuray’s New TomoTherapy H Series of Radiation Oncology Devices

Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, today launched its new TomoTherapy® H™ Series, featuring the TomoHDA™ System, with faster planning, faster delivery and increased quality. The TomoHDA System was unveiled at the 54th Annual American Society for Radiation Oncology (ASTRO) Meeting in Boston. Key features of the TomoHDA System include:

Accuray’s new TomoEDGE™ dynamic jaws technology provides users with added flexibility in treatment delivery by sharpening dose fall off and accuracy. In many cases the use of TomoEDGE for head and neck tumors and prostate cancer treatments has resulted in the reduction of beam-on time by half. With the TomoHDA™ System this new technology is standard and can be applied to both TomoHelical™ and TomoDirect™ treatment modes for 3DCRT and IMRT deliveries.

The high-performance VoLO™ Technology – an enhancement to the TomoTherapy® treatment planning system – leverages the new dose calculation algorithm and advanced graphics processing technology to increase clinical efficiency, throughput and flexibility in developing both simple and the most complex radiation therapy plans.

“We are committed to our TomoTherapy customers and continue to innovate to provide the most advanced treatments in radiation oncology with the goal of improving patient care,” said Joshua H. Levine, president and chief executive officer of Accuray. “The new TomoTherapy H™ Series offers treatment solutions for the entire spectrum of radiation therapy. It will enable unprecedented speed and efficiency ensuring the highest quality of care from the routine to the most complex cases.”

The TomoHDA System is a fully-integrated 3D image-guided, full spectrum radiation therapy system and builds upon the proven TomoTherapy Hi-Art® and TomoHD™ technologies. The TomoHDA System offers multiple new benefits including performance enhancements, unrivaled dose distributions and faster treatments.

The TomoHDA System is part of the new TomoTherapy H Series. Included in this series of products, is the new TomoH™ System, the gold standard for image-guided IMRT (intensity-modulated radiation therapy) treatment, providing streamlined 3D CT daily image guidance and ultrafast MLC (multileaf collimator) modulation, enabling the delivery of the dose to achieve excellent target homogeneity while sparing surrounding healthy tissue. Also included in the series is the TomoHD™ System – including TomoDirect – a full spectrum solution that provides high quality treatments to every patient for any clinical indication requiring radiotherapy.

The new TomoEDGE™ dynamic jaws are capable of sharpening the dose and allow customers to treat more patients with the TomoTherapy System. The jaws are optimized to sweep across the target, minimizing dose to healthy tissue and critical structures adjacent to the target and opening to the desired maximum size to reduce treatment time. The result is a balanced treatment delivery that is as unique as each patient.

Using the high-performance VoLO Technology, the TomoHDA™ system allows ultra fast creation of highly conformal treatment plans with the flexibility to design a personalized treatment plan specific to the individual needs of each patient. For example, the application of VoLO technology on breast cancer treatment plans has been shown to reduce dose calculation and treatment planning optimization time to as few as three minutes. TomoHDA also includes a fan-beam computed tomography (CT) system capable of producing images 50 percent faster, facilitating improved patient re-positioning time and therefore less overall time for the patient to be on the treatment couch.

“Having been involved in the creation of and research collaboration for the new TomoEDGE, we have seen firsthand that this is one of the most versatile radiation therapy treatment options available,” said PD Dr. Florian Sterzing, M.D., Consultant Radiation Oncologist at University Clinic of Heidelberg. “The new functionality enables improved quality of radiotherapy application and allows us to treat even more cancer patients.”

The TomoHDA System also includes Citrix®-based remote planning with web-based review capabilities, providing the ultimate flexibility for clinicians to develop and approve treatment plans from virtual workstations.

“TomoTherapy’s ability to treat the full range of disease sites, including even the most complex tumors, makes it an invaluable resource for cancer patients,” said Wade Gebara, M.D. Chief of Radiation Oncology at Berkshire Medical Center, Pittsfield, Mass. “With increased speed and reliability, the new TomoTherapy System will provide the opportunity for more patients to benefit from this personalized technology.”

Also on display in Accuray’s ASTRO booth (#7101) is the CyberKnife M6 FIM Sytem – part of the CyberKnife® M6™ Series – which is pending FDA 510(k) clearance and not yet available for commercial distribution in the United States. The new CyberKnife M6 FIM and FM Systems feature the InCise™ Multileaf Collimator, which combines the benefits of beam shaping with the flexibility of non-isocentric, non-coplanar delivery. The new InCise Multileaf Collimator (MLC) was designed specifically for stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) treatments, giving the system the capability to extend its radiosurgical precision into a broader field of applications. The system is intended to treat large and irregular tumors more efficiently with excellent dose gradients, to expand the number of patients eligible for treatment.

Researchers at Fox Chase Cancer Center in Philadelphia – who compared treatment plans created with a theoretical MLC on the CyberKnife System to those created originally with the CyberKnife Iris™ Collimator and conventional Intensity-Modulated Radiation Therapy (IMRT) plans – found that an MLC mounted on a robotic arm could potentially offer numerous clinical benefits, including faster treatment delivery, better target coverage and a sharper dose fall off could be achieved than a typical gantry- based IMRT plan or previous CyberKnife treatments. The Fox Chase researchers demonstrated the potential to create treatment plans that would spare critical structures around tumors better with a robotically mounted MLC, providing the ability to treat tumors using a higher dose without increasing the normal tissue toxicity.

Dates, times and locations of ASTRO clinical presentations featuring the CyberKnife and TomoTherapy Systems are available here.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is the premier radiation oncology company that develops, manufactures and sells personalized innovative treatment solutions that set the standard of care, with the aim of helping patients live longer, better lives. The Company’s leading edge technologies – the CyberKnife and TomoTherapy Systems – are designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy, and adaptive radiation therapy. To date 642 systems have been installed in leading hospitals around the world. For more information, please visit www.accuray.com.

Safe Harbor Statement

Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to expansion of the Company’s global presence, quality of treatments, accuracy, dose delivery, clinical efficiency, continual innovation, pending regulatory clearance, treatment times, dose sculpting, and the Company’s leadership position in radiation oncology innovation. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including risks detailed from time to time under the heading “Risk Factors” in the company’s report on Form 10-K filed on September 10, 2012. Forward-looking statements speak only as of the date the statements are made and are based on information available to the Company at the time those statements are made and/or management’s good faith belief as of that time with respect to future events. The Company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not place undue reliance on any forward-looking statements.

The TomoTherapy® System, the premier solution for the entire spectrum of radiation therapy — that delivers dose only where you need it — now with outstanding speed, performance and simplicity — allowing you the freedom to choose the very best treatment for each of your patients, with confidence and without compromise.

Created to make personalized treatments an option for radiation therapy, the TomoTherapy H Series offers interactive planning and efficient delivery of highly sculpted doses for personalized and consistent treatments. Seamless daily CT image guidance provides precise patient positioning, margin reduction and adaptive planning and enables pinpoint dose accuracy for every radiation therapy patient.

Accuray launched its new TomoTherapy H Series line of radiation oncology devices, headlined by the 3D image guided TomoHDA System with TomoEDGE technology. TomoEDGE optimizes radiation delivery by sharpening the affected edge between the target tumor and healthy tissue.

Accuray TomoTherapy H Series table Accurays New TomoTherapy H Series of Radiation Oncology Devices (VIDEO)

The company’s VoLO technology takes into account the new radiation dose delivery pattern into its calculations when doing graphic analysis in preparing treatment plans.

The three devices in the TomoTherapy H Series:

The TomoHDA™ System – the ultimate flexibility in treatment delivery with unrivaled dose conformality, faster patient treatments, and faster concurrent treatment planning. It grants everypatient access to high quality treatment

TomoEDGE™ spares more normal tissue while enabling increased throughput —with unprecedented quality

High performance VoLO™ planning provides flexibility, speed, efficiency and interactivity for concurrent treatment planning

Expand your practice by efficiently treating patients that are difficult to treat with conventional radiation therapy equipment

The TomoHD™ System- the full spectrum solution for any Radiation Oncology center, providing high quality treatments to every patient for any clinical indication requiring radiotherapy

TomoHelical™ and TomoDirect™ modalities to enable delivery of individualized treatments for both routine and complex indications

VoLO planning provides the ultimate in flexibility, speed and efficiency with real time interactive planning

The clinical solution when accuracy, flexibility and efficiency cannot be compromised

The TomoH™ System- the gold standard for image guided IMRT treatment delivery maximizes both conformality and target dose uniformity

CTrue™ image guidance provides daily 3D CT target localization and enables margin reduction while sparing healthy tissue

Ultra-fast binary MLC enables unprecedented intensity modulation

Excellent target homogeneity while sparing more normal healthy tissue

Source : http://www.accuray.com/media/press-releases/accuray-launches-new-tomotherapy%C2%AE-h%E2%84%A2-series-featuring-tomoedge%E2%84%A2

Full story

Endo-microscopy from Mauna Kea Technologies

Endo-microscopy from Mauna Kea Technologies

Endo-microscopy from Mauna Kea Technologies

A research team from the State University of New York at Buffalo has created nanoparticles that deliver genes into neurons in the brains of living mice “with an efficiency that is similar to, or better than, viral vectors and with no observable toxic effect.” The research, published in the current issue of the Proceedings of the National Academy of Sciences, could potentially revolutionize diagnosis and treatment of neurologic disorders.

From the press release:

The paper describes how the UB scientists used gene-nanoparticle complexes to activate adult brain stem/progenitor cells in vivo, demonstrating that it may be possible to “turn on” these otherwise idle cells as effective replacements for those destroyed by neurodegenerative diseases, such as Parkinson’s.

In addition to delivering therapeutic genes to repair malfunctioning brain cells, the nanoparticles also provide promising models for studying the genetic mechanisms of brain disease…

The UB researchers make their nanoparticles from hybrid, organically modified silica (ORMOSIL), the structure and composition of which allow for the development of an extensive library of tailored nanoparticles to target gene therapies for different tissues and cell types.

A key advantage of the UB team’s nanoparticle is its surface functionality, which allows it to be targeted to specific cells, explained Dhruba J. Bharali, Ph.D., a co-author on the paper and post-doctoral associate in the UB Department of Chemistry and UB’s Institute for Lasers, Photonics and Biophotonics.

While they are easier and faster to produce, non-viral vectors typically suffer from very low expression and efficacy rates, especially in vivo.

“This is the first time that a non-viral vector has demonstrated efficacy in vivo at levels comparable to a viral vector,” Bharali said.

In the UB experiments, targeted dopamine neurons — which degenerate in Parkinson’s disease, for example — took up and expressed a fluorescent marker gene, demonstrating the ability of nanoparticle technology to deliver effectively genes to specific types of cells in the brain.

Using a new optical fiber in vivo imaging technique (CellviZio developed by Mauna Kea Technologies of Paris), the UB researchers were able to observe the brain cells expressing genes without having to sacrifice the animal.

I came across a company called Mauna Kea Technologies.

They recently released the “GI” and “Lung” version of their cellular-level Cellvizio confocal endoscope.

What is great about the new GI and Lung Cellvizios is that a practitioner can insert one of their miniprobes (only 300 um to 2.8 mm in diameter) into a conventional endoscope and record microscopic level movies of the tissue as fast as 12 frames/sec.

The Image Atlas at http://www.maunakeatech.com contains several movies recorded by medical research labs and clinical practitioners in the US and in Europe. The recordings show an impressive level of detail. Their web site also mentions that they recently signed a distribution deal with Leica for their Small Animal imaging system.

Source : http://www.maunakeatech.com/

Related Posts Plugin for WordPress, Blogger...

Full story

Page 1 of 3123
Copyright © 2017 Medical Technology & Gadgets Blog MedicalBuy.net. All rights reserved.
Proudly powered by WordPress. Developed by Deluxe Themes